1-3 of 3
Brian F. Kabat
Close
Sort by
Journal Articles

Sensitivity of Ibrutinib Exposed Chronic Lymphocytic Leukemia B-Cells to Inhibition of Axl Receptor Tyrosine Kinase

Sutapa Sinha, PhD, Justin C Boysen, Kari G. Chaffee, MS, Brian F Kabat, Susan L. Slager, PhD, Sameer A. Parikh, MD, Charla R Secreto, Tait D. Shanafelt, MD, Jose F. Leis, MD PhD, Steven L. Warner, PhD, David J. Bearss, PhD, Asish K Ghosh, PhD, Neil E. Kay, MD
Journal: Blood
Blood (2016) 128 (22): 2020.
https://doi.org/10.1182/blood.V128.22.2020.2020
Published: 2016
Journal Articles

The Role of Splenectomy in the Care and Treatment of the CLL Patient

Michael J Conte, PA-C, Sameer A. Parikh, MD, Deborah A. Bowen, APRN, CNP, Timothy G. Call, MD, Brian F Kabat, Kari G Chaffee, MS, Susan M. Schwager, Susan L. Slager, PhD, Wei Ding, MD PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD
Journal: Blood
Blood (2016) 128 (22): 5575.
https://doi.org/10.1182/blood.V128.22.5575.5575
Published: 2016
Journal Articles

Alemtuzumab and Rituximab for Initial Treatment of High Risk, Early Stage Chronic Lymphocytic Leukemia (CLL).

Clive S. Zent, MD, Timothy G. Call, MD, Tait D. Shanafelt, MD, Diane F. Jelinek, PhD, Renee C. Tschumper, Charla R. Secreto, Deborah A. Bowen, RN, Susan M. Geyer, PhD, Brian F. Kabat, Betsy R. LaPlant, Wenting Wu, PhD, Neil E. Kay, MR
Journal: Blood
Blood (2007) 110 (11): 2050.
https://doi.org/10.1182/blood.V110.11.2050.2050
Published: 2007